地西他滨联合化疗治疗急性髓系白血病的疗效

目的探讨地西他滨联合CAG方案化疗治疗老年急性髓系白血病的疗效及安全性。方法选择2017年6月—2018年6月期间本院收治的老年AML患者86例,采用随机数字表法分为两组,各43例。对照组采用CAG方案化疗,研究组在此基础上加用地西他滨。两组化疗周期均为2周,且均持续化疗2个周期。对比两组临床疗效及安全性,并比较两组实验室指标LDH、HBDH、IFN-γ改善情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);两组治疗后LDH、HBDH、IFN-γ水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组治疗期间化疗相关不良反应发生率略高于对照组,除发热外,差异无统计学意义(P>0.05)。结论地西他滨联合CAG方案化疗治疗老年急性髓系白血病疗效好于单用CAG方案,虽增加相关不良反应,但可耐受。

Efficacy of Decitabine Combined With Chemotherapy in the Treatment of Acute Myeloid Leukemia

Objective To investigate the efficacy and safety of desitabine combined with CAG regimen in the treatment of elderly acute myeloid leukemia.Methods 86 elderly patients with AML admitted to our hospital from June 2017 to June 2018 were divided into two groups by random number table,43 cases each.The control group was treated with CAG regimen,and the study group was treated with ceftazidime on the basis of CAG regimen.The chemotherapy cycles of the two groups were 2 weeks,and both groups received continuous chemotherapy for 2 cycles.The clinical efficacy and safety of the two groups were compared,and the improvement of laboratory indicators LDH,HBDH and IFN-gamma in the two groups were compared.Results The total effective rate of the observation group was higher than that of the control group,with statistical significance(P<0.05);the levels of LDH,HBDH and IFN-gamma in the two groups were lower than those before treatment,and the observation group was lower than that of the control group,with statistical significance(P<0.05);the incidence of chemotherapy-related adverse reactions in the observation group was slightly higher than that in the control group,except for fever,the difference was not statistically significant(P>0.05).Conclusion Dicetabine combined with CAG regimen is better than CAG regimen alone in the treatment of elderly acute myeloid leukemia.Although it increases the related adverse reactions,it is tolerable.